

<<心脏病学>>

图书基本信息

书名：<<心脏病学>>

13位ISBN编号：9787506222280

10位ISBN编号：7506222280

出版时间：2000-1

出版时间：任卫军 世界图书出版公司 (2000-01出版)

作者：任卫军 编

版权说明：本站所提供下载的PDF图书仅提供预览和简介，请支持正版图书。

更多资源请访问：<http://www.tushu007.com>

<<心脏病学>>

书籍目录

Contributors	IXForeword	XVIIPreface	XIXSECTION
IBASIC FOUNDATIONSOF CARDIOLOGYChapter IIntroduction: the changing face of cardiology 3Peter SleightChapter 2EpidemiologyPrancois Delahaye, Gay de Gevigney, Jacques DelayeChapter 3Physiology of circulation Thomas KennerChapter 4Psychologic stress and the heart Richard L. Verrier, Murray A. MittlemanChapter 5Principles of drug therapy Lajos MatosChapter 6Rehabilitation Catherine MonpereSECTION 2CLINICAL EVALUATIONAND SPECIAL INVESTIGATIONSChecker 7History and symptoms Jean-Pierre DelahayeChapter 8The physical examination of thecardiovascular system.....			

## &lt;&lt;心脏病学&gt;&gt;

## 章节摘录

书摘 · Disopyramide (additive effect) . · General anesthetics (negative inotropic effect) .  
 · Lidocaine (unwanted lidocaine effects may be exaggerated) . · MAO inhibitors (increased hypotensive effect) . · NSAIDs (antihypertensive action may be decreased) . · Quinidine (beta blocking effect may be increased) . · Rifampicin (beta-blocker plasma levels may be reduced) . Dosage See Table 5  
 · **NONSELECTIVE BETA-BLOCKERS WITH ISA** alprenolol, carteolol, oxprenolol, penbutolol, pindolol . Some are lipid-soluble (e.g., alprenolol, oxprenolol), are metabolized extensively by the liver, have relatively short half-lives, and need to be administered in several daily doses (Tab. 5. 8) . Advantages  
 · Resting heart rate is decreased less than after administration of beta-blockers without ISA . · Cardiac output at rest is depressed to only a minor degree . · In this subgroup resting blood pressure is lowered more by a fall in peripheral resistance than by a decrease in cardiac output . · Exacerbation of anginal symptoms following discontinuation of treatment is less likely with beta-blockers having a moderate / high ISA (no up-regulation of the receptor) . · Adverse reactions (e.g., cold extremities, fatigue) may be less frequent . · Increase in serum cholesterol and triglycerides and decrease in HDL cholesterol are less likely . · Little effect on the resting heart rate . therefore . less effective in reducing mortality . · Less effective antianginal activity, especially at night (then an increase in heart rate may occur, prolonging ischemic episodes) . · Ventricular fibrillation threshold lowers (relatively) . See nonselective beta-blockers without ISA Dosage See Table 5 .  
 · **SELECTIVE BETA-BLOCKERS WITHOUT ISA** atenolol, betaxolol, bisoprolol, esmolol, metoprolol . Of these (Tab. 5. 9), some are relatively lipid soluble (e.g., metoprolol) . are metabolized by the liver, and have a short half-life . thus requiring special formulation for once-a-day tablets . Others are rather hydrophilic (e.g., atenolol), minimally metabolized, excreted by the kidneys . have longer duration of action, and are sufficient for once-daily administration . Advantages . The lack of beta<sub>1</sub>-blocking effects makes beta<sub>2</sub> vasodilatation possible, and therefore beta<sub>1</sub>-selective drugs decrease diastolic blood pressure slightly more (3-4 mm Hg) than do non-selective agents . · Lesser impairment of exercise tolerance (beta<sub>2</sub>-blocking effects on muscle glycolytic processes) . · Fewer adverse reactions in patients with a tendency to bronchospasm, diabetes, or peripheral vascular disease . · Esmolol has a rapid onset and a very short half-life (Tab. 5. 9) and is indicated mainly for fast ventricular-rate control in patients when short-term control of the heart rate is necessary (e.g. atrial fibrillation or atrial flutter) . Disadvantages Fall in cardiac output (20-25%), which remains at these levels throughout chronic therapy . · Second and third-degree atrioventricular block . · Severe bradycardia (condition may worsen) . · Severe peripheral vascular disease (cardiac output is decreased, which could lead to further worsening) . · Uncontrolled heart failure (may be exacerbated) . · Severe asthma (may be exacerbated) . · Pregnancy . · Myocardial infarction with bradycardia (further negative chronotropic effect) . · Hypotension (may be exacerbated) . · Epinephrine (sudden hypertension with bradycardia, less likely than with nonselective drugs) . · Antiarrhythmics (Class I: cardiac depression and bradycardia) . · C: calcium antagonists (especially diltiazem and verapamil: additive negative chronotropic and inotropic action, hypotension) . · Enzyme inhibitors (e.g., cimetidine may increase plasma levels of metabolites) .  
 · Clonidine (rebound hypertension when clonidine is withdrawn, although less likely than with nonselective beta-blockers) . . . . . 书摘1 . . . . .

<<心脏病学>>

媒体关注与评论

书评.....

<<心脏病学>>

版权说明

本站所提供下载的PDF图书仅提供预览和简介，请支持正版图书。

更多资源请访问:<http://www.tushu007.com>